*Please note you are registering an interest to attend this event and will receive a confirmation email if your place is approved in due course.

While populations around the world are living longer and we better survive disease such as cancer, multimorbidity is an emerging global health priority. Around 1 in every 4 of all adults in the UK are now living with two or more chronic medical conditions and the associated burden of polypharmacy. The impacts on patient outcomes are widely disproportionate across the UK with multimorbidity presenting on average 10-15 years earlier in disadvantaged populations.

The majority of diagnostics, therapeutics and digital healthcare technologies currently being  developed target specific disease indications within separate patient interventions.

The vision to be discussed at this workshop is how an expanding knowledge of disease clusters and the biomarkers that underpin them can transform market opportunities and growth for UK businesses developing diagnostics, therapeutics and digital solutions that are optimised and made available to all patients with multiple long-term conditions, regardless of socioeconomic status. Advances in pharmacogenomic capabilities that inform personalised sensitivity to drugs and ease the burden of polypharmacy will also be discussed.

If you would like to contribute to this critical discussion, please register your Expression of Interest for either or both of the following workshops.

Day 1: Challenges and opportunities for better detection, diagnosis and clinical management of multimorbidity

The focus of this session is to explore how the UK health system is currently responding to the increasing number of patients with multiple long-term conditions and the impacts of healthcare inequalities on patient outcomes. We will also explore opportunities for businesses to bring about much needed innovations in the prevention, early diagnosis and management of multi-morbidity.

Breakout sessions

1. How to achieve an equitable, inclusive, patient-centred management of multimorbidity.
2. Support for business-led innovation: how to create an environment where multimorbidity solutions can be adopted?
3. Population health and integrated care / outcomes based care: how can we deliver better management of multimorbidity in this evolving healthcare ecosystem?

Day 2: Innovation to optimise therapeutic options for prevention and treatment of multimorbidity

The focus of this day is to explore unmet clinical needs in the effective treatment and therapy of patients with multiple long term conditions. Such patients have been historically excluded from clinical trials and also suffer from the burden of polypharmacy complications that affect quality of life. Innovation that supports a more holistic and personalised intervention, that applies patient stratification and pharmacogenomics, could dramatically improve health outcomes for diverse patient groups.

Breakout sessions

1. Challenges and opportunities of delivering personalised treatment for multimorbid patients (including role of pharmacogenomics and polypharmacy)
2. Real world clinical trials: how can we support a more inclusive approach?
3. How to translate complex data into meaningful clinical decision support?

Register